These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27061947)

  • 1. Injection site reactions after subcutaneous oligonucleotide therapy.
    van Meer L; Moerland M; Gallagher J; van Doorn MB; Prens EP; Cohen AF; Rissmann R; Burggraaf J
    Br J Clin Pharmacol; 2016 Aug; 82(2):340-51. PubMed ID: 27061947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis.
    González-López MA; Martínez-Taboada VM; González-Vela MC; Blanco R; Fernández-Llaca H; Rodríguez-Valverde V; Val-Bernal JF
    Clin Exp Dermatol; 2007 Nov; 32(6):672-4. PubMed ID: 17953638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of histopathological findings at the injection site following degarelix administration.
    Maeda T; Kosaka T; Honda A; Okata U; Hayakawa N; Ito Y; Nagata H; Chen KR; Nakamura S; Oya M
    Support Care Cancer; 2015 May; 23(5):1377-81. PubMed ID: 25358643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection site reactions with the use of biological agents.
    Thomaidou E; Ramot Y
    Dermatol Ther; 2019 Mar; 32(2):e12817. PubMed ID: 30637967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study.
    Hilhorst N; Spanoudi-Kitrimi I; Goemans N; Morren MA
    Eur J Pediatr; 2019 Feb; 178(2):253-258. PubMed ID: 30448867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations.
    Kaiser C; Knight A; Nordström D; Pettersson T; Fransson J; Florin-Robertsson E; Pilström B
    Rheumatol Int; 2012 Feb; 32(2):295-9. PubMed ID: 21881988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.
    Stewart TM; Tran ZV
    Int J MS Care; 2012; 14(1):46-53. PubMed ID: 24453732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
    Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
    Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment.
    Batycka-Baran A; Flaig M; Molin S; Ruzicka T; Prinz JC
    Expert Opin Drug Saf; 2012 Nov; 11(6):911-21. PubMed ID: 22998733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing incidences of infusion site reactions between brand-name and generic vinorelbine in patients with non-small cell lung cancer.
    Ozawa N; Hase T; Hatta T; Sagara A; Ichikawa K; Miyazaki M; Yogo N; Ando M; Hashimoto N; Yamada K; Hasegawa Y
    Br J Clin Pharmacol; 2021 Mar; 87(3):1318-1326. PubMed ID: 32790917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
    Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
    Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
    Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
    J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.
    Zeltser R; Valle L; Tanck C; Holyst MM; Ritchlin C; Gaspari AA
    Arch Dermatol; 2001 Jul; 137(7):893-9. PubMed ID: 11453808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
    Kamimura T; Miyamoto T; Yokota N; Takashima S; Chong Y; Ito Y; Akashi K
    Eur J Haematol; 2013 Feb; 90(2):157-61. PubMed ID: 23240903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
    Gottlieb M; Thommes JA;
    Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.
    Shear NH; Paul C; Blauvelt A; Gooderham M; Leonardi C; Reich K; Ohtsuki M; Pangallo B; Xu W; Ball S; Ridenour T; Torisu-Itakura H; Agada N; Mallbris L
    J Drugs Dermatol; 2018 Feb; 17(2):200-206. PubMed ID: 29462229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study.
    Megna M; Battista T; Noto M; Picone V; Fabbrocini G; Ruggiero A; Genco L
    Clin Cosmet Investig Dermatol; 2023; 16():553-564. PubMed ID: 36896374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta injection site reactions in patients with multiple sclerosis.
    Maurelli M; Bergamaschi R; Antonini A; Fargnoli MC; Puma E; Mallucci G; Totaro R; Girolomoni G
    J Dermatolog Treat; 2018 Dec; 29(8):831-834. PubMed ID: 29671656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe persistent injection site reactions after subcutaneous 2'-O-methyl phosphorothioate oligonucleotide therapy for Duchenne muscular dystrophy.
    Domingos J; Ricotti V; Martinez AE; Muntoni F
    Neuromuscul Disord; 2018 Feb; 28(2):176-177. PubMed ID: 29305134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.